Shai Novik, Executive Chairman of the Board

Mr. Novik founded PROLOR Biotech in 2005, and has served as its President until 2014. Mr. Novik founded PROLOR Biotech in 2005, and has served as its President until 2014.  PROLOR Biotech was listed on NYSE in 2010 and was sold in 2013, the second largest biotech exit in the history of Israeli biotech.

Mr. Novik previously served as Chief Operating Officer and Head of Strategic Planning of THCG, Inc., a technology and life sciences investment company. THCG was a portfolio company of Greenwich Street Partners, one of the largest U.S. private equity funds. THCG’s own portfolio included several life sciences and medical devices companies. Prior to his position at THCG, Mr. Novik served as Chief Operating Officer and Chairman of Strategy Committee of RogersCasey, an investment advisory company that served pension funds of Fortune 500 companies such as DuPont, Kodak, General Electric and others. Mr. Novik received his M.B.A, with distinction, from the Cornell University.

Udi Eyal Fima, Ph.D., MBA, President & CEO

Dr. Fima is the President & CEO of Enlivex, and has served on its board of directors since March 2014. Previously, from 2005 through 2015, Dr. Fima was Vice President, Product Development, COO and then CEO of PROLOR Biotech.Mr. Novik founded PROLOR Biotech in 2005, and has served as its President until 2014.  PROLOR Biotech was listed on NYSE in 2010 and was sold in 2013, the second largest biotech exit in the history of Israeli biotech.

Dr. Fima also co-founded NatSpears Ltd., a company specializing in cancer therapeutics, and served as its CEO from 2002 to 2005. Prior to founding NatSpears, Dr. Fima was a research fellow at the Immunology Department of Ben-Gurion University in Israel from 2000 to 2002, where he researched the involvement of signal transduction in breast cancer. Dr. Fima received his Ph.D. in immunotherapeutic protocols and cytokine regulation from Ben-Gurion University’s Medical School in Israel, and an M.B.A. from the Ben-Gurion University’s Business School.

Prof. Dror Mevorach, M.D., Founder, Chief Scientific & Medical Officer

Professor Dror Mevorach is Director of the Rheumatology Research Centre, and Chairman of Medicine at the Hadassah – Hebrew University Medical Center in Jerusalem. A member of several international medical and scientific societies, Dr. Mevorach has been investigating the role of apoptosis and cytokines for the past 18 years, and is a world leader in apoptosis research. He has published over 90 scientific papers in his field and is a frequent lecturer at international conferences around the world. Dr. Mevorach received his MD (Cum Laude) from the Technion university in Israel.

Shachar Shlosberger, C.P.A., M.B.A., Chief Financial Officer

Mrs. Shlosberger has served as the CFO of Enlivex since 2016, bringing with her more than 10 years of Financial Experience in Hi-Tech and Bio-Tech Industry. Prior Enlivex Shachar worked for 4 years at PROLOR Biotech Ltd  as Finance Director where she was responsible for the overall financial operations in Israel and US. Mrs. Shlosberger is a Certified Public Accountant and holds a M.B.A. in Accounting and Business Administration from the College of Management in Israel.

Chaya Mazouz, M.P.H, Vice President, Regulatory & Quality Assurance

Mrs. Mazouz brings a broad range of biotechnology clinical and quality assurance expertise, as well as broad related experience. Prior to joining Enlivex, Mrs. Mazouz was Head of Quality and Regulatory Affairs position in LipoCure, a biothech company engaged in developing a number of highly-potent therapeutics utilizing proprietary liposome-based nano-drugs with novel drug-loading-capabilities and drug-release mechanisms; VP Clinical and Regulatory Affairs at Pluristem Ltd., a bio-therapeutics company dedicated to the commercialization of allogeneic cell therapy products derived from human placenta; Clinical Operations Director at Medgenics, a clinical-stage biopharmaceutical company involved in gene therapy, where she engineered and managed Phase I/II clinical studies; Clinical Manager for TransPharma Medical, a drug delivery company, where she was responsible for managing clinical activities. In previous positions, she led a multi-center Phase II study for Pharmos, a pharmaceutical company, and was CRA and Project Manager at IDgene, a startup company engaged in gene discovery. Mrs. Mazouz received  a B.Sc., and Masters Degree in Public Health from the Hebrew University in Jerusalem.

Adi Tabib, M.Sc., Head of Development and Manufacturing

Ms. Tabib has served as the Head of Development and Manufacturing at Enlivex since 2007. She researched her M.Sc.’s thesis at Prof. Dror Mevorach’s laboratory.Ms. Tabib received her M.Sc. in Microbiology from the Hebrew University in Jerusalem.

Veronique Amor Baroukh, Ph.D., Head of Research

Mrs. Amor Baroukh has served as Head of Research at Enlivex since 2015, immediately after having received her Ph.D. degree from the Weizmann Institute of Science. She conducted her research in the field of molecular neurobiology, focusing on the molecular mechanisms of myelination. Prior to her studies at the Weizmann Institute, Veronique obtained her B.Sc. at McGill University, in Montreal, Canada (Honors program, Department of Microbiology and Immunology).